Showing results (1-10 of 13) with videos related to
Sort By:
Pageof 2
Circulation|November 28, 2001
Estrogen-induced vasoprotection is independent of inducible nitric oxide synthase expression: evidence from the mouse carotid artery ligation modelT Tolbert, J A Thompson, P Bouchard, et al.The Journal of Air Medical Transport|June 8, 1990
International air medical transport. Part I: Methods and logisticsW F Holdefer, A G Diethelm, J T TolbertThe Journal of Air Medical Transport|July 8, 1990
International air medical transport. Part II: Results and discussionW F Holdefer, A G Diethelm, J T TolbertJournal of Perinatology : Official Journal of the California Perinatal Association|January 1, 2008
Campomelic dysplasia: case report and reviewM Gimovsky, E Rosa, T Tolbert, et al.Cell Death & Disease|October 21, 2018
Targeting enhancer of zeste homolog 2 protects against acute kidney injuryX Zhou, X Zang, Y Guan, et al.Antimicrobial Agents and Chemotherapy|April 17, 2001
Safety and pharmacokinetics of single doses of (+)-calanolide a, a novel, naturally occurring nonnucleoside reverse transcriptase inhibitor, in healthy, human immunodeficiency virus-negative human subjectsT Creagh, J L Ruckle, D T Tolbert, et al.Experimental and Clinical Psychopharmacology|March 26, 2026
Neurobehavioral differences in value-based decision making between people with cocaine use disorder and controlsJoshua A Lile, Preston T Tolbert, Thomas P Shellenberg, et al.The Journal of Biological Chemistry|October 26, 2000
The C-terminal tail of UNC-60B (actin depolymerizing factor/cofilin) is critical for maintaining its stable association with F-actin and is implicated in the second actin-binding siteS Ono, A McGough, B J Pope, et al.HIV Clinical Trials|December 26, 2002
Safety and pharmacokinetic profile of multiple escalating doses of (+)-calanolide A, a naturally occurring nonnucleoside reverse transcriptase inhibitor, in healthy HIV-negative volunteersDavid A Eiznhamer, Terri Creagh, Jon L Ruckle, et al.Pageof 2